We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Test Diagnoses Pancreatic Cancer Disease Earlier

By LabMedica International staff writers
Posted on 29 Jan 2019
Print article
Image: Immunocytochemistry using anti- TRA-1-60 antibody (Photo courtesy of Novus Biologicals).
Image: Immunocytochemistry using anti- TRA-1-60 antibody (Photo courtesy of Novus Biologicals).
Pancreatic cancer is difficult to diagnose because it often does not have obvious early symptoms; as by the time the disease is found, it typically is quite advanced, complicating treatment and leading to poorer outcomes.

Only 8.5% of people with pancreatic cancer survive past five years, a figure that has risen just slightly since the early 1990s. A new, simple blood test has been developed that, when combined with an existing test, detects nearly 70% of pancreatic cancers with a less than 5% false-positive rate.

Scientists at the Van Andel Research Institute (Grand Rapids, MI, USA) and their colleagues collected blood samples from patients with pancreatic cancer or a benign condition involving the pancreas, and from healthy subjects. The team combined the current biomarker Carbohydrate antigen CA19-9 with a sialylated keratan sulfate proteoglycan sugar called sTRA that was measured by the new test, which is produced by a different subset of pancreatic cancers.

The team developed candidate biomarkers from sTRA and CA19-9 in a training set of 147 plasma samples and used the panels to make case/control calls, based on predetermined thresholds, in a 50-sample validation set and a blinded, 147-sample test set. The team used sandwich immunoassays utilizing antibody array methods with slight modifications. The capture antibodies were CA19-9, anti-MUC5AC, and anti-MUC16. The biotinylated primary antibodies were CA19-9 from MyBioSource or TRA-1-60.

The scientists reported that the two biomarker panels improved upon CA19-9 in the training set, one optimized for specificity, which included CA19-9 and two versions of the sTRA assay, and another optimized for sensitivity, which included two sTRA assays. Both panels achieved statistical improvement over CA19-9 in the validation set, and the specificity-optimized panel achieved statistical improvement in the blinded set: 95% specificity and 54% sensitivity (75% accuracy), compared to 97%/30% (65% accuracy). When the data was unblinded it produced further improvements and revealed independent, complementary contributions from each marker.

The authors concluded that sTRA is a validated serological biomarker of pancreatic ductal adenocarcinoma (PDAC) that yields improved performance over CA19-9. The new panels may enable surveillance for PDAC among people with elevated risk, or improved differential diagnosis among patients with suspected pancreatic cancer. Brian Haab, PhD, a professor and the study’s leading author, said, “We hope that our new test, when used in conjunction with the currently available test, will help doctors catch and treat pancreatic cancer in high-risk individuals before the disease has spread.” The study was published online on January 7, 2019, in the journal Clinical Cancer Research.

Related Links:
Van Andel Research Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.